EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Adverse events after riboflavin/UV-A corneal cross-linking: a literature review

Sebastiano Serrao, Giuseppe Lombardo, Marco Lombardo

International Ophthalmology · 2022-01 · 42 (1) · 337-348

DOI: 10.1007/s10792-021-02019-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Ophthalmology, online erschienen am 27.08.2021. Verfasst von Sebastiano Serrao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Studio Italiano di Oftalmologia, Via Livenza 3, 00198, Rome, Italy. serrao@serraolaser.it. Hauptthemen laut MEDLINE: Keratoconus, Photochemotherapy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Riboflavin/UV-A corneal cross-linking (CXL) for treating keratoconus and iatrogenic corneal ectasia has been well-established as first treatment option to stabilize corneal tissue biomechanical instability. Although the plethora of clinical studies has been published into the field, there is no systematic review assessing the type and frequency of adverse events after CXL. METHODS: A systemic literature review on clinical safety and adverse events after CXL in patients with keratoconus and corneal ectasia was performed using PubMed. A literature search was performed for relevant peer-reviewed publications. The main outcome measures extracted from the articles were adverse events, endothelial cell density, corrected distance visual acuity and maximum simulated keratometry. RESULTS: The most frequent adverse events after CXL were corneal haze and corneal edema, which were mild and transient. The severe adverse events were infrequent (cumulative incidence: < 1.3%) after CXL. The clinical benefits of CXL highly outweighed the risks for the treatment of keratoconus and corneal ectasia. CONCLUSIONS: The severe adverse events with permanent sequelae are infrequent after CXL and all are associated with corneal de-epithelialization, such as infectious keratitis and corneal scarring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KeratoconusPhotochemotherapyCollagenCorneal TopographyCross-Linking ReagentsHumansPhotosensitizing AgentsRiboflavinUltraviolet Rays

Stichwörter der Autor:innen

Adverse eventsCorneal cross-linkingCorneal ectasiaKeratoconusRiboflavin

Substanzen

Cross-Linking ReagentsPhotosensitizing AgentsCollagenRiboflavin

Autor:innen und Institutionen

  • Studio Italiano di Oftalmologia, Via Livenza 3, 00198, Rome, Italy. serrao@serraolaser.it.
  • Vision Engineering Italy srl, Via Livenza 3, 00198, Rome, Italy. serrao@serraolaser.it.
  • Vision Engineering Italy srl, Via Livenza 3, 00198, Rome, Italy.
  • CNR-IPCF, Istituto per i processi Chimico-Fisici, Viale F. Stagno D'Alcontres 37, 98158, Messina, Italy.
  • Studio Italiano di Oftalmologia, Via Livenza 3, 00198, Rome, Italy.

Zitieren

APA

Serrao, S., Lombardo, G., & Lombardo, M. (2022). Adverse events after riboflavin/UV-A corneal cross-linking: a literature review. International Ophthalmology, 42(1), 337-348. https://doi.org/10.1007/s10792-021-02019-1

Vancouver

Serrao S, Lombardo G, Lombardo M. Adverse events after riboflavin/UV-A corneal cross-linking: a literature review. International Ophthalmology. 2022;42(1):337-348. doi:10.1007/s10792-021-02019-1

BibTeX
@article{Serrao2022,
  author = {Serrao, Sebastiano and Lombardo, Giuseppe and Lombardo, Marco},
  title = {Adverse events after riboflavin/UV-A corneal cross-linking: a literature review},
  journal = {International Ophthalmology},
  year = {2022},
  volume = {42},
  number = {1},
  pages = {337--348},
  doi = {10.1007/s10792-021-02019-1}
}
Kostenlos starten →